Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

• Main Authors: Patrizia Murer (Author), Barbara Brannetti (Author), Jean-Michel Rondeau (Author), Laetitia Petersen (Author), Nicole Egli (Author), Simone Popp (Author), Catherine Regnier (Author), Kirsten Richter (Author), Andreas Katopodis (Author), Christoph Huber (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 antibody fusion protein designed for selective IL-2...